BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research

Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. Lunit's presentations this year will highl...

November 08, 2022 | News

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met ...

November 07, 2022 | News

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

November 07, 2022 | News

NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is announc...

November 03, 2022 | News

Australia First in-human use of OncoRes Medical's cancer imaging system successful

OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled&n...

November 03, 2022 | News

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

If adopted, the rule would eliminate all cost to Medicare patients for a follow-up colonoscopy after a positive at-home colorectal cancer screening test. A...

November 02, 2022 | News

T-cells treated by Turn Biotechnologies show increased cancer-killing effectiveness

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today presents interim pre-c...

October 25, 2022 | News

Irish oncology care platform announces collaboration with NCCN

The Irish-founded oncology software company, ONCOassist, today announces a new agreement with The National Comprehensive Cancer Network® (NCCN®). T...

October 18, 2022 | News

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...

October 17, 2022 | News

Health Canada Approves Illuccix® for Prostate Cancer Imaging

Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...

October 14, 2022 | News

First patient treated in Clarity's therapeutic prostate cancer trial

Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...

October 10, 2022 | News

United Imaging Announces Clinical System Installations at Huntsman Cancer Institute at the University of Utah

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced that The Center for Quantitative Cancer Imaging ...

September 16, 2022 | News

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

September 14, 2022 | News

Merck to Highlight Data at ESMO 2022 with Potential for Transformative Impact on Cancer Patients

Late-breaking data highlight 5-year survival results from Phase II study of the investigational IAP inhibitor xevinapant in the curative setting of unres...

September 08, 2022 | News

Stay Connected